Literature DB >> 6726370

Dorsal root entry zone lesions for the treatment of post-herpetic neuralgia.

A H Friedman, B S Nashold, J Ovelmen-Levitt.   

Abstract

Post-herpetic pain was treated in 12 patients using dorsal root entry zone ( DREZ ) lesions. All patients had failed to receive adequate pain relief from conservative therapy consisting of transcutaneous nerve stimulation, carbamazepine, and/or amitriptyline. Dorsal root entry zone lesions were made to include the involved dermatomes plus one-half of the dermatomes above and below the painful areas. Eight patients reported good pain relief with follow-up periods ranging from 6 to 21 months. A ninth patient obtained satisfactory pain relief, but the superior 1 cm of the original painful area was not included in the distribution of the DREZ lesions. Patients whose lesions were performed using a thermally controlled lesion probe suffered no significant postoperative neurological deficit. Dorsal root entry zone lesions appeared to be a satisfactory treatment for post-herpetic neuralgia in patients who have failed to respond to more conservative modes of therapy.

Entities:  

Mesh:

Year:  1984        PMID: 6726370     DOI: 10.3171/jns.1984.60.6.1258

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  4 in total

1.  Treatment of shingles and post-herpetic neuralgia.

Authors:  C Schieff
Journal:  BMJ       Date:  1989-07-01

2.  Experimental radiofrequency (RF) coagulation with computer-based on line monitoring of temperature and power.

Authors:  J R Moringlane; R Koch; H Schäfer; C B Ostertag
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

3.  [Pain therapy in herpes zoster and post-zoster neuralgia.].

Authors:  T Zenz; M Zenz; M Tryba
Journal:  Schmerz       Date:  1994-03       Impact factor: 1.107

Review 4.  Post herpetic neuralgia: a review.

Authors:  M J Griffin; F A Chambers; R MacSullivan
Journal:  Ir J Med Sci       Date:  1998 Apr-Jun       Impact factor: 2.089

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.